---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-215459"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T06:54:29.257661+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantheus discontinues AZEDRA production; winds down Somerset, NJ site

## Summary
- Progenics Pharmaceuticals subsidiary to stop manufacturing and promoting AZEDRA.
- Limited usage and fixed costs made continued production untenable.
- Goal to supply current patients through Q1 2024 to complete treatment.
- Somerset, NJ manufacturing site being wound down.
- No financial impact or restructuring charges disclosed.

## SEC filing metadata
- accession: 0001193125-23-215459
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312523215459/0001193125-23-215459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312523215459/d300211d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-215459
- JSON: https://secwatch.observer/filing/0001193125-23-215459.json
- Plain text: https://secwatch.observer/filing/0001193125-23-215459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.